Want to join the conversation?
In 1Q16, $VRTX plans to commence a clinical trial for KALYDECO (ivacaftor) in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. $VRTX has submitted a supplemental New Drug Application, sNDA, for KALYDECO and a target review date for the sNDA is set for Feb. 6, 2016.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.